This medication is used to manage serious bacterial infections, providing symptomatic support in conditions where symptoms create noticeable physiological strain. It is relevant for use in treating serious conditions such as tuberculosis (TB), as well as specific, rare zoonotic diseases like Plague and Tularemia.

The medication is relevant in conditions characterized by periods of heightened symptoms, and helps address symptom clusters that interfere with daily functioning. It is used for managing symptoms related to systemic imbalance, including persistent fever and weakness (malaise), and is relevant for easing symptoms linked to organ-specific functional stress, such as severe cough and painful, swollen lymph glands. This use provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load.

“This therapy is applied in clinical settings that involve acute or unstable symptom patterns, which may benefit from supportive symptom management.”

---

Quick Fact: Symptomatic Support for Systemic Discomfort

It is often used when symptoms intensify and supportive relief is needed, and supports the patient during difficult episodes by easing distress.

Who Can and Cannot Use Streptomisin?

Official regulatory documents strictly define the eligible population for Streptomisin (Streptomycin sulfate). Use is contraindicated in patients with a history of clinically significant hypersensitivity to Streptomycin or to any other aminoglycoside antibiotic. The medicine is also strictly contraindicated in pregnancy due to the known risk of fetal harm, and in patients with pre-existing labyrinthine disease.

Populations requiring restricted or conditional use include those with impaired renal function or pre-renal azotemia, which necessitates cautious administration and a reduced dosage with close monitoring. Patients with pre-existing auditory dysfunction or impaired VIII cranial nerve function also require special caution due to the risk of neurotoxicity. Older adults and young infants require caution and potential dose adjustments due to age-related physiological factors. For breastfeeding women, use is restricted, requiring a decision to either discontinue the medicine or discontinue nursing. These limitations establish the formal criteria for use as defined by regulatory authorities.

Interactions with other medicines and products

Streptomisin's interaction profile is governed primarily by its potential for additive toxicity and its dependence on renal clearance, as outlined in official regulatory documents.

Pharmacodynamic Interactions (Toxicity Risk)

Co-administration with other neurotoxic or nephrotoxic medicinal products is officially constrained and generally should be avoided due to the risk of severe, additive toxicity. This includes other aminoglycosides (e.g., Gentamicin), Capreomycin, and substances like Ciclosporin and Cisplatin.

Interaction with Loop Diuretics (e.g., Furosemide or Ethacrynic acid) is also constrained, as co-administration potentiates the ototoxic effects of Streptomisin. Furthermore, this medicine potentiates the effects of Neuromuscular Blocking Agents and General Anesthetics, leading to an increased risk of respiratory paralysis.

Pharmacokinetic and Timing Constraints

The risk of drug accumulation and severe neurotoxic reactions is sharply increased in patients with impaired renal function, a population-specific consideration noted in prescribing information. Amiodarone may increase Streptomisin's exposure through a P-glycoprotein transporter interaction. Procedurally, Streptomisin and beta-Lactam Antibiotics must not be admixed in an intravenous solution due to physical in vitro inactivation. No known formal interactions have been documented with common foods or drinks.

How Streptomycin Works

Streptomycin's core mechanism is its irreversible binding to the bacterial 30S ribosomal subunit, specifically targeting the 16S ribosomal RNA. This interaction functions as a potent inhibitor of bacterial protein synthesis. The binding initiates a lethal cascade by blocking the initiation of protein creation and simultaneously inducing widespread misreading of messenger RNA (mRNA). This results in the incorporation of incorrect amino acids into polypeptide chains.

The production of these numerous misfolded and non-functional proteins destabilizes the entire bacterial cell structure, leading to rapid loss of cellular integrity. This irreversible intracellular damage culminates in the decisive bactericidal effect—the swift killing of the microorganism. The resulting physiological consequence is the decisive reduction of the susceptible pathogen load.

A key mechanistic constraint is that the drug's initial uptake across the bacterial cell membrane requires an active, oxygen-dependent transport process. Consequently, the bactericidal mechanism is significantly impaired or rendered ineffective against strict anaerobic bacteria, demonstrating a direct link between the drug's mechanism of action and the local oxygen levels required for transport.

Streptomycin is an injection-only medication. Its use follows specific administration and dosing protocols. The medicine is supplied as a sterile powder for injection, which must be reconstituted by a healthcare professional with sterile water before use.

Administration and Dosing Principles

Category	Administration Guidelines
Route of Administration	Deep intramuscular (IM) injection is the standard route for systemic action. Injection sites, such as the upper outer quadrant of the buttock or mid-lateral thigh, must be alternated to minimize local irritation.
Dosing Schedule	Dosing is typically weight-based, such as 15 mg/kg for daily regimens, with the dose usually not exceeding a 1 gram maximum per day. Doses are given either daily or intermittently (such as two to three times per week), depending on the specific treatment protocol.
Duration of Use	The total course length depends on the infection, ranging from 7 to 14 days for certain conditions, up to at least one year when used for tuberculosis. The total dose over a lifetime should generally not exceed 120 grams.

Population-Specific Adjustments

Dose adjustments are required in specific patient groups. For older adults (aged over 59), the daily dose is typically reduced to not exceeding 750 mg. For patients with impaired renal function, both the dosage amount and the frequency interval must be modified based on calculated creatinine clearance, often extending the interval between injections. The drug must be administered under the immediate supervision of a healthcare professional in a clinical setting.

Streptomisin is an aminoglycoside antibiotic that holds a specific, specialized role in the modern treatment of several serious bacterial infections. As the first effective antibiotic against Mycobacterium tuberculosis (TB), its historical significance is substantial, and clinical evidence continues to support its targeted use today.

Approved Indications and Efficacy

The drug is approved for a limited number of severe infections, primarily used as part of combination therapy to prevent antimicrobial resistance and enhance outcomes:

Approved Indication	Role in Current Treatment	Evidence Summary
Tuberculosis (TB)	Second-line agent for multi-drug resistant (MDR) TB, or when first-line drugs cannot be used.	Meta-analyses suggest that when drug susceptibility test results support its use, Streptomisin is associated with improved cure rates in MDR-TB regimens compared to some other injectable agents.
Plague	First-line therapeutic option for all forms of plague (Yersinia pestis).	Decades of clinical use and comparative studies support its efficacy, often serving as the benchmark against which newer alternatives are measured.
Tularemia	Considered a primary drug option for this serious infection (Francisella tularensis).	Clinical experience demonstrates effectiveness, though the emergence of alternatives like gentamicin and fluoroquinolones has prompted ongoing comparative assessments.

Comparative Findings and Role

Clinical trials examining the treatment of MDR-TB suggest that Streptomisin and amikacin are associated with better outcomes than other injectable agents like kanamycin or capreomycin, when the isolate is susceptible. However, due to the established risk of irreversible ototoxicity (hearing and balance problems) and nephrotoxicity (kidney damage), its use requires careful patient selection and rigorous clinical monitoring. Its role in regimens for infective endocarditis remains important, often used synergistically with penicillins.

Common questions about Streptomisin (FAQ)

Q: When is the reconstituted Streptomisin solution no longer safe to use?

According to official product information, once the Streptomisin powder has been mixed with sterile water (reconstituted), it should be stored in a refrigerator. The solution is considered stable for 96 hours, or four days, under these refrigerated conditions. Any unused portion of the medication must be discarded after this time limit.

Q: What is the exact maximum daily dose of Streptomisin for a healthy adult?

Regulatory documents state that for the treatment of serious infections, the maximum total daily amount of Streptomisin should generally not exceed 2 grams. This dose is typically administered by dividing it into smaller, more frequent injections. The patient's treating healthcare provider determines the specific dose for the individual based on their specific condition and needs.

Q: Why can’t I mix Streptomisin with penicillin?

Official labeling advises that Streptomisin should not be physically combined in the same syringe or solution with beta-Lactam antibiotics, which include penicillin. This is because mixing these agents can lead to an in vitro inactivation, which is a chemical process where the antibiotics counteract each other, rendering the product inactive prior to administration.

Q: How does the dosage of Streptomisin change for patients with kidney issues?

For patients with impaired kidney function, regulatory prescribing information requires the dosage to be carefully modified and reduced. This adjustment involves decreasing the amount of medicine given and/or extending the time interval between injections. These changes are based on clinical tests of kidney function to reduce the risk of drug accumulation.

Q: What is the primary difference between ototoxicity and nephrotoxicity caused by Streptomisin?

Streptomisin’s official safety information highlights two primary risks: ototoxicity and nephrotoxicity. Ototoxicity refers to potential damage to the inner ear, which can affect hearing and balance and may be irreversible. Nephrotoxicity refers to potential harm to the kidneys, which can lead to impaired kidney function or, in rare cases, acute failure. Both effects are serious adverse reactions that require clinical monitoring.

Q: Can Streptomisin be used to treat viral infections?

Streptomisin is an antibacterial drug that is only approved and indicated for the treatment of specific bacterial infections. As an antibacterial drug, it is not effective against infections caused by viruses, such as the common cold or flu.

The sterile Streptomycin Sulfate powder for injection must be stored in its original container at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F).

Condition	Requirement
Unreconstituted Powder	Store at Controlled Room Temperature (20 C–25 C) in original container.
Reconstituted Solution	Stable for 96 hours (4 days) only when refrigerated at 4 C (39 F). Do not freeze.

All forms of the medicine must be kept out of the sight and reach of children.

Disposal of any unused product or waste must adhere strictly to local requirements. The medicine should not be disposed of in household waste or flushed down a sink or toilet; instead, it must be discarded through an authorized pharmaceutical waste or drug take-back program.